Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 583 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 583 shares of the firm's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $22.46, for a total transaction of $13,094.18. Following the completion of the sale, the chief financial officer now owns 187,727 shares of the company's stock, valued at $4,216,348.42. This trade represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, April 9th, Troy Wichterman sold 932 shares of BioLife Solutions stock. The shares were sold at an average price of $20.11, for a total transaction of $18,742.52.
• On Tuesday, April 1st, Troy Wichterman sold 25,687 shares of BioLife Solutions stock. The shares were sold at an average price of $22.66, for a total transaction of $582,067.42.
• On Tuesday, March 11th, Troy Wichterman sold 4,151 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $103,775.00.
• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total transaction of $16,803.60.

BioLife Solutions Stock Performance

BioLife Solutions stock traded down $0.49 during trading hours on Friday, hitting $21.83. The company had a trading volume of 786,262 shares, compared to its average volume of 389,684. The firm has a market cap of $1.04 billion, a PE ratio of -20.59 and a beta of 2.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions, Inc. has a one year low of $18.70 and a one year high of $29.55. The firm has a 50-day moving average of $22.86 and a 200 day moving average of $25.07.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. The firm had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. On average, sell-side analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. D.A. Davidson & CO. increased its holdings in shares of BioLife Solutions by 1.3% during the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after purchasing an additional 519 shares during the period. Sei Investments Co. increased its holdings in shares of BioLife Solutions by 0.5% during the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider's stock worth $2,695,000 after purchasing an additional 547 shares during the period. Rhumbline Advisers increased its holdings in shares of BioLife Solutions by 0.7% during the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after purchasing an additional 566 shares during the period. GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after purchasing an additional 663 shares during the period. Finally, 1620 Investment Advisors Inc. increased its holdings in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 675 shares during the period. 93.24% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $31.17.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.